To the Editor We read with interest the article “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial” by Bonner et al.1 We congratulate the authors on their phase 3 clinical trial, however, some potentially misleading ambiguities can be noticed in their article.